Payment overview · 2025
General Payments
$93.98
4 reported records · 3 companies
Healthcare provider profile · identity verified
Inna Petrosova, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1609861004
Verified facts
What the public records show
CMS Open Payments records show Inna Petrosova, MD received $93.98 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.32 | 42.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.33 | 32.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.33 | 24.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $93.98 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.32 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.32 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 438 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 425 | 107 |
| Gabapentin | Gabapentin | 414 | 95 |
| Omeprazole | Omeprazole | 383 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 43 |
| Repaglinide | Repaglinide | 309 | 62 |
| Losartan Potassium | Losartan Potassium | 247 | 55 |
| Baclofen | Baclofen | 233 | 85 |
| Meloxicam | Meloxicam | 226 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 45 |
| Nifedipine Er | Nifedipine | 205 | 39 |
| Allopurinol | Allopurinol | 198 | 34 |
| Linzess | Linaclotide | 180 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 173 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 171 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 35 |
| Celecoxib | Celecoxib | 165 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 31 |
| Memantine Hcl | Memantine Hcl | 154 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 152 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 33 |
| Famotidine | Famotidine | 139 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 23 |
| Risedronate Sodium | Risedronate Sodium | 119 | 26 |
| Montelukast Sodium | Montelukast Sodium | 108 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 103 | 18 |
| Carvedilol | Carvedilol | 102 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 46 |
| Atenolol | Atenolol | 101 | 19 |
| Furosemide | Furosemide | 101 | 19 |
| Enalapril Maleate | Enalapril Maleate | 88 | 13 |
| Simvastatin | Simvastatin | 88 | 17 |
| Meclizine Hcl | Meclizine Hcl | 86 | 26 |
| Januvia | Sitagliptin Phosphate | 84 | 15 |
| Eliquis | Apixaban | 80 | 13 |
| Vascepa | Icosapent Ethyl | 80 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 62 |
| Colchicine | Colchicine | 74 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 21 |
| Metformin Hcl | Metformin Hcl | 69 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 20 |
| Potassium Chloride | Potassium Chloride | 68 | 14 |
| Alendronate Sodium | Alendronate Sodium | 67 | 12 |
| Chlorthalidone | Chlorthalidone | 67 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 17 |
| Azithromycin | Azithromycin | 65 | 53 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 65 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 62 | suppressed |
| Valsartan | Valsartan | 60 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 55 | 13 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Finasteride | Finasteride | 52 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 51 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Clonidine | Clonidine | 49 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 44 | 21 |
| Zenpep | Lipase/Protease/Amylase | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | 12 |
| Dexilant | Dexlansoprazole | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Multaq | Dronedarone Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Prednisone | Prednisone | 25 | 14 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93.98 · 4 records | Amgen Inc. | FARXIGA, HORIZANT, OTEZLA, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error